ASX ANNOUNCEMENT **31 July 2026**

EBR provides additional information regarding recent reports

Santa Clara, California; 31 July 2026: EBR Systems, Inc. (ASX: "**EBR**", "**EBR Systems**" or the "**Company**") has completed its internal investigation of the recent events that occurred at one site where two patients suffered serious complications following the implantation of the WiSE® system. During next-day, post-implant, transthoracic echocardiograms (TTE), each patient separately developed ventricular fibrillation. One patient could not be resuscitated and died.

The online speculation was based on mandatory event reporting by the site involved and was not a review from the U.S. Food and Drug Administration (**"FD**A"). The FDA will review the events utilising information provided by the site and the results of EBR's internal investigation, which has just concluded. EBR made multiple attempts to obtain additional clinical records from the site but received no response and no information for review. A summary of EBR's analysis will appear publicly on FDA's MAUDE database in accordance with FDA's posting schedule.

The Company's final internal assessment concludes that this is an **isolated event** related to a **disclosed risk** that **can be mitigated** when following recommended TTE (imaging) procedures **per the device labelling and training**. To date, the only occurrences in the commercial experience have been the two that occurred at one site on the same day. The rate of occurrence during commercial implants remains below historic rates as reported in the premarket approval (PMA) application submitted to FDA for WiSE approval. There have been no previous reports of patient death due to this complication.

WiSE Labelling

The FDA-approved WiSE System Common IFU (LBL-05300 Rev B) outlines precautions for exposure to ultrasound sources, including TTE, describes the hazard associated with untimed pacing, and provides considerations for ultrasound imaging. This hazard — external ultrasound-induced stimulation arising from the WiSE System's passive acoustic operating principle — is known, previously identified, and occurs at a low frequency.

During the PMA process, FDA also reviewed and provided input on the Alternative Echo Protocol (LBL-10003 Rev A). This outlines the procedure for safely performing TTE.

Both the Common IFU and the Alternative Echo Protocol describe safe use of TTE and require that the patient be monitored at all times with ECG, that an external defibrillator be available, and that the probe be immediately removed from the patient if unintended stimulation occurs. The Echo Protocol also describes methods of using lower energy TTE settings if external ultrasound-induced stimulation is detected by ECG. These precautions are included in all physician and hospital training programs. Additionally, patients are provided with an ID card that includes a link to this information.

Given the final conclusions of the Company's internal assessment, EBR has no ongoing concern at this stage. Commercial implants are continuing at other sites in the usual course.

Investor Webinar

As previously shared, EBR's senior management team will host an investor webinar to discuss this announcement and the Company's Preliminary Q2 2026 Results. The webinar will be held on **Friday 31 July 2026 at 10:00am AEST (Thursday 30 July at 5:00pm PDT).**

Investors can register for the webinar via the following link:

https://attendee.gotowebinar.com/register/2361333619071585888

After registering, you will receive a confirmation email containing information about joining the webinar.

This announcement has been authorised for release by the EBR Systems General Disclosure Committee, a Committee of the Board of Directors.

ENDS

For more information, please contact:

Company
Andrew Shute
Chief Corporate Development Officer
P: +44 7730 691421
E: investor.relations@ebrwise.com

Investor Relations
Gabriella Hold
The Capital Network
P: +61 2 7257 7338
E: gaby@thecapitalnetwork.com.au

About EBR Systems (ASX: EBR)

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems' WiSE Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products and achieve broad market adoption including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. These forward-looking statements are based on EBR Systems' current expectations and inherently involve significant risks and uncertainties. EBR Systems' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in its most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC from time to time and available on the

SEC's website at www.sec.gov.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's ASX-traded (ASX: EBR) CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.